Cadrenal Therapeutics, Inc.2025财年第一财季实现净利润-3.85百万美元，同比减少131.93%

市场透视2025-05-18

5月18日，Cadrenal Therapeutics, Inc.（CVKD.US）公布财报，公告显示公司2025财年第一财季净利润为-3.85百万美元，同比减少131.93%；其中营业收入为0.00美元，每股基本收益为-2.09美元。从资产负债表来看，Cadrenal Therapeutics, Inc.（CVKD.US）总负债1.84百万美元，其中短期债务0.00美元，资产负债比为4.33，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2536258441?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-18 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2536258441","market":"us","top_or_hot":-1,"title":"Cadrenal Therapeutics, Inc.2025财年第一财季实现净利润-3.85百万美元，同比减少131.93%","media":"市场透视","content":"<div>\n<p>5月18日，Cadrenal Therapeutics, Inc.（CVKD.US）公布财报，公告显示公司2025财年第一财季净利润为-3.85百万美元，同比减少131.93%；其中营业收入为0.00美元，每股基本收益为-2.09美元。从资产负债表来看，Cadrenal Therapeutics, Inc.（CVKD.US）总负债1.84百万美元，其中短期债务0.00美元，资产负债比为4.33，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000229a6e2d855&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cadrenal Therapeutics, Inc.2025财年第一财季实现净利润-3.85百万美元，同比减少131.93%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCadrenal Therapeutics, Inc.2025财年第一财季实现净利润-3.85百万美元，同比减少131.93%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-18 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000229a6e2d855&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月18日，Cadrenal Therapeutics, Inc.（CVKD.US）公布财报，公告显示公司2025财年第一财季净利润为-3.85百万美元，同比减少131.93%；其中营业收入为0.00美元，每股基本收益为-2.09美元。从资产负债表来看，Cadrenal Therapeutics, Inc.（CVKD.US）总负债1.84百万美元，其中短期债务0.00美元，资产负债比为4.33，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000229a6e2d855&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CVKD","symbol_name":"Cadrenal Therapeutics, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000229a6e2d855&s=b","article_id":"2536258441","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000229a6e2d855&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2536258441","pubTimestamp":1747497632,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月18日，Cadrenal Therapeutics, Inc.公布财报，公告显示公司2025财年第一财季净利润为-3.85百万美元，同比减少131.93%；其中营业收入为0.00美元，每股基本收益为-2.09美元。机构评级：截至2025年5月18日，当前有3家机构对Cadrenal Therapeutics, Inc.目标价做出预测，其中目标均价为35.67美元，其中最低目标价为30.00美元，最高目标价为45.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"CVKD":"Cadrenal Therapeutics, Inc.","LENZ":"Therapeutics"},"translate_title":"Cadrenal Therapeutics, Inc. achieved net profit of-US $3.85 million in the first fiscal quarter of fiscal 2025, a year-on-year decrease of 131.93%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"CVKD":1},"content_text":"5月18日，Cadrenal Therapeutics, Inc.（CVKD.US）公布财报，公告显示公司2025财年第一财季净利润为-3.85百万美元，同比减少131.93%；其中营业收入为0.00美元，每股基本收益为-2.09美元。从资产负债表来看，Cadrenal Therapeutics, Inc.（CVKD.US）总负债1.84百万美元，其中短期债务0.00美元，资产负债比为4.33，流动比率为4.32。机构评级：截至2025年5月18日，当前有3家机构对Cadrenal Therapeutics, Inc.目标价做出预测，其中目标均价为35.67美元，其中最低目标价为30.00美元，最高目标价为45.00美元。公司简介：Cadrenal Therapeutics Inc正在开发其候选药物tecarfarin，以满足抗凝治疗中尚未满足的需求。Tecarfarin是一种后期新型口服可逆抗凝剂（血液稀释剂），旨在预防需要长期抗凝治疗的罕见心血管疾病患者因血栓导致的心脏病突发、中风和死亡。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2536258441","isCrawlerRequest":true}